Samsca Liver Injury Warning Issued By FDA

Irvin Jackson

Add Your Comments

Federal drug experts are placing a one month limit on the recommended use of Samsca, a hyponatremia drug that has been linked to a risk of liver damage.  

The FDA issued a drug safety communication (PDF) on April 30, indicating that Samsca should not be used for longer than 30 days. The agency also warned that the drug should not be used in patients with underlying liver disease.

Samsca side effects have been associated with a potential risk of severe liver injury, which could result in the need for a liver transplant or death, according to the warning.

Do You Know about…

SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS

Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Do You Know About…

SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS

Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Along with the announcement, the FDA announced that it is updating the Samsca warning label to included a 30 day limit on use, the contraindication for patients with liver disease, and descriptions of liver problems from Samsca seen during clinical trials. The label will also recommend that doctors discontinue use when a patient shows signs of liver injury.

Samsca (tolvaptan) is an Otsuka Pharmaceutical Co. drug approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, a condition that results in critically low salt levels. It belongs to a family of drugs known as selective vasopressin V2-receptor antagonists.

There have been about 16,000 prescriptions for Samsca since it was approved in May 2009.

The FDA began looking at the drug’s safety profile after Otsuka sent out a Dear Healthcare Provider letter (PDF) on January 22, warning that Samsca liver injury could be permanent and fatal. The letter came after three clinical trial patients suffered liver damage while taking the drug. All three recovered after they stopped taking Samsca.

The FDA now believes that Samsca can cause serious and fatal liver injury. The agency warned doctors to look for signs of liver injury among patients taking Samsca. Samsca patients should talk to their doctor if they experience:

  • Loss of appetite
  •  Nausea or vomiting
  •  Fever
  •  Unusual fatigue
  •  Itching
  •  Yellowing of the skin or eyes
  •  Unusually dark urine
  •  Pain in the right upper abdomen
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Liver Damage, Liver Injury, Otsuka Pharmaceutical Co, Samsca

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Proposed Depo-Provera Lawsuit Schedule Calls for First Trial in Dec. 2026
Lawyers involved in Depo-Provera litigation have agreed to hold the first bellwether trial over brain tumor injuries beginning on December 7, 2026.
Insole-Foot-Warmer-Burns-Often-Require-Debridement
Defective heated insoles and electric socks have been linked to severe foot burns that required surgical debridement, with lawsuits now alleging long-term nerve damage and mobility loss.